Want to see AU:CMB full AI Analyst Report?
CMB Stock Chart & Stats
AU$0.47
-AU$0.02(-4.44%)
At close: 4:00 PM EST
AU$0.47
-AU$0.02(-4.44%)
Day’s Range― - ―
52-Week RangeAU$0.26 - AU$0.60
Previous CloseN/A
Volume21.69K
Average Volume (3M)3.93K
Market Cap
AU$11.07M
Enterprise ValueAU$9.50M
Total Cash (Recent Filing)AU$774.31K
Total Debt (Recent Filing)AU$413.56K
Price to Earnings (P/E)―
Beta-3.47
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding27,331,919
10 Day Avg. Volume7,693
30 Day Avg. Volume3,926
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.09
Price to Sales (P/S)5.73
P/FCF Ratio-0.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Regenerative Platform & IPRegeneus’s integrated platform—proprietary cell therapies, manufacturing capability and IP—creates structural competitive advantages for commercialization in musculoskeletal indications. Ownership of manufacturing and IP supports margins, partner deals and barriers to entry over the medium term.
Revenue Rebound With High Gross MarginA sharp revenue rebound alongside a ~69% gross margin demonstrates the underlying product economics can be attractive at scale. Durable high gross margins indicate a scalable cost structure for therapies, supporting improving unit profitability as commercialization and volumes expand.
Low Financial LeverageModerate leverage with low absolute debt reduces interest burden and preserves strategic flexibility. For a clinical-stage biotech burning cash, limited debt lowers near-term solvency pressure and allows management to prioritize R&D/commercial programs without heavy fixed financing costs.
Bears Say
Ongoing Large Operating LossesSustained multi-million dollar operating losses weaken internal funding capacity and erode returns. Persistent negative margins mean the business must rely on external capital to sustain R&D and commercial expansion, increasing execution risk and potential dilution over the next several quarters.
High Cash Burn And Weak Cash GenerationSignificant negative operating and free cash flow indicate the company is consuming cash much faster than it generates revenue. This structural cash burn tightens runway, raises frequent financing needs, and constrains the firm’s ability to fund trials, manufacturing scale-up or commercialization without dilutive raises.
Shrinking Equity And Prior Solvency StressFalling equity and a history of negative equity signal past solvency stress and heighten the likelihood of future dilutive financings. Weakening shareholder equity undermines balance-sheet resilience, complicates partner negotiations and raises long-term funding and governance risks.
Regeneus Ltd. News
CMB FAQ
What was Regeneus Ltd.’s price range in the past 12 months?
Regeneus Ltd. lowest share price was AU$0.26 and its highest was AU$0.60 in the past 12 months.
What is Regeneus Ltd.’s market cap?
Regeneus Ltd.’s market cap is AU$11.07M.
When is Regeneus Ltd.’s upcoming earnings report date?
Regeneus Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 45 days.
How were Regeneus Ltd.’s earnings last quarter?
Regeneus Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.07 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Regeneus Ltd. overvalued?
According to Wall Street analysts Regeneus Ltd.’s price is currently Overvalued.
Does Regeneus Ltd. pay dividends?
Regeneus Ltd. does not currently pay dividends.
What is Regeneus Ltd.’s EPS estimate?
Regeneus Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Regeneus Ltd. have?
Regeneus Ltd. has 27,331,919 shares outstanding.
What happened to Regeneus Ltd.’s price movement after its last earnings report?
Regeneus Ltd. reported an EPS of -AU$0.07 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Regeneus Ltd.?
Currently, no hedge funds are holding shares in AU:CMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Regeneus Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.22%
12-Months-Change
Fundamentals
Return on Equity
-218.76%
Trailing 12-Months
Asset Growth
-5.07%
Trailing 12-Months
Company Description
Regeneus Ltd.
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Technical Analysis
Cynata Therapeutics Limited
―
Living Cell Technologies
―
Mesoblast Limited
―
Orthocell Ltd
―
Tissue Repair Ltd
―
Options Prices
Currently, No data available
---